Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Retinal + niacinamide is a topical combination therapy primarily utilized in dermatological and cosmetic applications for the treatment of photoaging, acne, and skin texture irregularities. **Retinal** (retinaldehyde) is a direct precursor to retinoic acid; upon topical application, it undergoes a single-step enzymatic conversion within keratinocytes to its active form, which subsequently binds to retinoic acid receptors (RARs) to modulate gene expression, promote cellular turnover, and stimulate collagen synthesis. **Niacinamide** (nicotinamide) is a water-soluble form of vitamin B3 that serves as a precursor to the coenzymes NAD+ and NADP+. In the skin, niacinamide functions as an anti-inflammatory agent, enhances the synthesis of barrier-forming lipids (such as ceramides), and inhibits the transfer of melanosomes from melanocytes to keratinocytes. The combination is strategically formulated to leverage the potent anti-aging effects of retinal while utilizing niacinamide to mitigate the localized irritation, erythema, and dryness typically associated with retinoid therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on retinal + niacinamide.